MA58653B1 - USE OF A GLUTARIMIDE DERIVATIVE TO TREAT DISEASES RELATED TO ABERRANT INTERLEUKIN-6 ACTIVITY - Google Patents
USE OF A GLUTARIMIDE DERIVATIVE TO TREAT DISEASES RELATED TO ABERRANT INTERLEUKIN-6 ACTIVITYInfo
- Publication number
- MA58653B1 MA58653B1 MA58653A MA58653A MA58653B1 MA 58653 B1 MA58653 B1 MA 58653B1 MA 58653 A MA58653 A MA 58653A MA 58653 A MA58653 A MA 58653A MA 58653 B1 MA58653 B1 MA 58653B1
- Authority
- MA
- Morocco
- Prior art keywords
- activity
- aberrant
- interleukin
- diseases related
- treat diseases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 102000004889 Interleukin-6 Human genes 0.000 title abstract 3
- 108090001005 Interleukin-6 Proteins 0.000 title abstract 3
- 230000001594 aberrant effect Effects 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 3
- 229940100601 interleukin-6 Drugs 0.000 title abstract 3
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical class O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 title abstract 2
- 206010052015 cytokine release syndrome Diseases 0.000 abstract 3
- 208000025721 COVID-19 Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention se rapporte au domaine de la médecine et concerne un traitement de maladies associées à une activité aberrante l'interleukine-6 et au développement du syndrome de libération de cytokines (choc cytokinique), de préférence un traitement du covid-19, ainsi que d'autres maladies compliquées par une activité aberrante d'interleukine-6 et le développement d'un syndrome de libération de cytokines, ceci en utilisant un composé de 1-(2-(1-méthyl-1?-imidazol-4- yl)éthyl)pipéridine-2,6-dione (i). L'invention permet de créer un nouvel agent médicamenteux efficace pour le traitement de maladies associées au développement du syndrome de libération de cytokines.The present invention relates to the field of medicine and relates to treatment of diseases associated with aberrant interleukin-6 activity and the development of cytokine release syndrome (cytokine shock), preferably treatment of covid-19, as well as other diseases complicated by aberrant interleukin-6 activity and the development of cytokine release syndrome, using a 1-(2-(1-methyl-1?-imidazol-4- yl)ethyl)piperidine-2,6-dione (i). The invention makes it possible to create a new medicinal agent effective for the treatment of diseases associated with the development of cytokine release syndrome.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2020121363A RU2774928C2 (en) | 2020-06-26 | Use of glutarimide derivative for therapy of diseases associated with aberrant activity of interleukin-6 | |
PCT/RU2021/050170 WO2021262040A1 (en) | 2020-06-26 | 2021-06-18 | Use of a glutarimide derivative for treating diseases associated with aberrant interleukin-6 activity |
Publications (2)
Publication Number | Publication Date |
---|---|
MA58653A1 MA58653A1 (en) | 2023-07-31 |
MA58653B1 true MA58653B1 (en) | 2024-02-29 |
Family
ID=79281595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA58653A MA58653B1 (en) | 2020-06-26 | 2021-06-18 | USE OF A GLUTARIMIDE DERIVATIVE TO TREAT DISEASES RELATED TO ABERRANT INTERLEUKIN-6 ACTIVITY |
Country Status (6)
Country | Link |
---|---|
CN (1) | CN115803026A (en) |
BR (1) | BR112022026356A2 (en) |
CL (1) | CL2022003725A1 (en) |
CO (1) | CO2023000604A2 (en) |
MA (1) | MA58653B1 (en) |
WO (1) | WO2021262040A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023177329A1 (en) * | 2022-03-18 | 2023-09-21 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Use of 1-(2-(1н-imidazole-4-yl)ethyl)piperidine-2,6-dione to treat cough caused by viral infections |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2112716A1 (en) * | 1971-03-17 | 1972-10-05 | Thomae Gmbh Dr K | Biphenylyl-butyric acid derivs. - anti phlogistics |
DE10002509A1 (en) * | 2000-01-21 | 2001-07-26 | Gruenenthal Gmbh | New substituted glutarimide derivatives are IL-12 antagonists, are useful as immunomodulators and for the treatment of angiopathy, hematological or oncological disorders |
UA115431C2 (en) * | 2011-10-11 | 2017-11-10 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Use of glutaryl histamine to treat respiratory tract infections |
CN102432544B (en) * | 2011-11-17 | 2014-05-21 | 天津医科大学 | 5-substituted benzyl methylene imidazole alkyl-2,4-diketone derivative and application thereof |
BR112015025804B1 (en) * | 2013-04-12 | 2022-01-04 | Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises" | GLUTARIMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED ON THEM AND METHODS FOR THE PRODUCTION OF GLUTARIMIDE DERIVATIVES |
RU2552929C1 (en) * | 2013-11-14 | 2015-06-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Pharmaceutical composition, containing derivatives of glutarimides, and their application for treatment of eosinophilic diseases |
US10739353B2 (en) * | 2014-12-31 | 2020-08-11 | Signpath Pharma, Inc. | Suppression of cytokine release and cytokine storm |
EA201992341A8 (en) * | 2017-09-07 | 2020-08-11 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | APPLICATION OF GLUTARIMIDE DERIVATIVES FOR TREATMENT OF DISEASES ASSOCIATED WITH ABERRANT CYTOKINE ACTIVITY |
TW202203917A (en) * | 2020-04-13 | 2022-02-01 | 加拿大健康網路大學 | Methods for treating cytokine release syndrome |
CN113582980B (en) * | 2020-04-30 | 2023-11-24 | 上海科技大学 | Compound based on heterocyclic ring and glutarimide skeleton and application thereof |
-
2021
- 2021-06-18 MA MA58653A patent/MA58653B1/en unknown
- 2021-06-18 CN CN202180044905.7A patent/CN115803026A/en active Pending
- 2021-06-18 WO PCT/RU2021/050170 patent/WO2021262040A1/en active Application Filing
- 2021-06-18 BR BR112022026356A patent/BR112022026356A2/en unknown
-
2022
- 2022-12-22 CL CL2022003725A patent/CL2022003725A1/en unknown
-
2023
- 2023-01-19 CO CONC2023/0000604A patent/CO2023000604A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2020121363A3 (en) | 2021-12-27 |
CO2023000604A2 (en) | 2023-01-26 |
MA58653A1 (en) | 2023-07-31 |
RU2020121363A (en) | 2021-12-27 |
WO2021262040A1 (en) | 2021-12-30 |
CL2022003725A1 (en) | 2023-05-19 |
CN115803026A (en) | 2023-03-14 |
BR112022026356A2 (en) | 2023-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202090955A1 (en) | METHODS OF USING EHMT2 INHIBITORS IN TREATMENT OR PREVENTION OF BLOOD DISORDERS | |
MA41496B1 (en) | Pharmaceutical compositions comprising n- (3,5-dimethoxyphenyl) -n '- (1-methylethyl) -n- [3- (1-methyl-1h-pyrazol-4-yl) quinoxalin-6-yl] ethane-1, 2-diamine | |
MA53399B1 (en) | Substituted pyrazoles as inhibitors of human plasma kallikrein | |
NO20025601D0 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
PE20040751A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING LOW DOSE OF AN INHIBITOR OF HUMAN TNFalpha | |
BR9810841A (en) | Alicyclic metalloprotease inhibitors | |
MA40814A1 (en) | Pharmaceutical compositions for combination therapy | |
HRP20050533A2 (en) | Aminoindazole derivatives and use thereof as kinase inhibitors | |
CY1124763T1 (en) | METHOD FOR THE THERAPEUTIC TREATMENT OF PRIMARY INSOMNIA | |
TNSN07063A1 (en) | THERAPEUTIC USES OF RTP801 INHIBITORS | |
JP2005532372A5 (en) | ||
MA28435B1 (en) | INDAZOLE CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | |
WO2001087328A3 (en) | Interleukin-1 inhibitors in the treatment of diseases | |
MXPA04001187A (en) | Interleukin-1 receptors in the treatment of diseases. | |
PE20050389A1 (en) | QUINOLINE AND QUINOXALINE COMPOUNDS | |
MA51627B1 (en) | Benzofuran, benzopyrrole, substituted benzothiophene and structurally related complement inhibitors | |
EA200600480A1 (en) | IMIDAZOPIRIDIN-SUBSTITUTE TROPANE DERIVATIVES, possessing the activity of the antagonist CCR5 Receptor, for the treatment of the human immunodeficiency virus (HIV) and inflammation | |
MY172303A (en) | Compositions and methods of use of phorbol esters | |
CL2004000366A1 (en) | USE OF A COMBINATION OF A QUINASA P38 INHIBITING DERIVED COMPOUND OF PIRAZOL, AND AN ACE INHIBITOR TO TREAT RENAL DYSFUNCTION, CARDIOVASCULAR AND VASCULAR DISEASE, RETINOPATHY, NEUROPATIA, EDOTEL, INSOTUNATIO OPINION. | |
EA200200591A1 (en) | PYRROLIDINES THAT INHIBIT CAMP-SPECIFIC PDE | |
MA47736B1 (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
MA58653B1 (en) | USE OF A GLUTARIMIDE DERIVATIVE TO TREAT DISEASES RELATED TO ABERRANT INTERLEUKIN-6 ACTIVITY | |
EA200201276A1 (en) | ARYLMETYLAMINE DERIVATIVES FOR USE AS TRIPTASE INHIBITORS | |
Machado Andrade et al. | Host and viral factors influencing interplay between the macrophage and HIV-1 | |
EA202191955A1 (en) | MODIFIED RELEASE TABLET FORMULATIONS CONTAINING PHOSPHODIESTERASE INHIBITORS |